Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 08, 2022 16:01 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
Arcellx Announces Pricing of Initial Public Offering
February 04, 2022 01:57 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Feb. 04, 2022 (GLOBE NEWSWIRE) -- Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients...
Arcellx Presents Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition
December 13, 2021 09:00 ET
|
Arcellx, Inc.
-- Two dose levels studied (100 and 300 million CAR+ T-cells); MTD not reached -- -- 100% ORR at both dose levels; deep and durable responses observed in patients with poor prognostic factors -- --...
Arcellx to Present New Clinical Data from its CART-ddBCMA Phase 1 Trial in Patients with Relapsed and Refractory Multiple Myeloma at the 63rd ASH Annual Meeting and Exposition
November 04, 2021 09:19 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Arcellx, Inc., a privately held clinical-stage biopharmaceutical company, today announced the presentation of new Phase 1 clinical trial data of...
Arcellx Announces Presentation of Positive Clinical Results from Ongoing Phase 1 Study of CART-ddBCMA at the 2021 ASCO Annual Meeting
June 04, 2021 09:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., June 04, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, announced the presentation of positive clinical data from the first 12...
Arcellx to Present Data from Phase 1 Study of CART-ddBCMA Demonstrating Continued Positive Response in Patients with Relapsed and Refractory Multiple Myeloma at the 2021 ASCO Annual Meeting
May 19, 2021 17:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., May 19, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced the release of updated clinical data from the first 12 evaluable...
Preclinical Data of Arcellx’s Novel Synthetic CAR-T Binding Domain Presented at the 2021 ASGCT Annual Meeting and the 2021 PEGS Summit
May 13, 2021 10:00 ET
|
Arcellx, Inc.
Novel synthetic binding domain used in CART-ddBCMA demonstrates potent anti-tumor activity Results underpin Arcellx’s ongoing first-in-human Phase 1 CART-ddBCMA trial in patients with relapsed and...
Arcellx Announces Executive Appointments
April 19, 2021 07:30 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., April 19, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it has hired two new executives to join the company’s...
Arcellx Closes $115 Million Series C Financing to Advance its Pipeline of Adaptive and Controllable Cell Therapies
April 13, 2021 07:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to...
Arcellx Announces FDA Clearance of IND Application for ACLX-001, a Controllable Cell Therapy Utilizing the Company’s ARC-SparX Platform, for the Treatment of Multiple Myeloma
April 06, 2021 16:00 ET
|
Arcellx, Inc.
GAITHERSBURG, Md., April 06, 2021 (GLOBE NEWSWIRE) -- Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared...